No Picture
News

Halozyme Reports Second Quarter 2019 Results

– Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period — ENHANZE® Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX® in the U.S. and EU — Pivotal Phase 3 Trial Results from… […]

No Picture
News

Evofem Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Amphora NDA Resubmission Remains on Track for Q4 2019Management to Host Conference Call Tuesday August 6, 2019 at 11:00 a.m. EDT

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) (“Evofem” or the “Company”), a clinical … […]

No Picture
News

Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8

SAN DIEGO, Aug. 1, 2019 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019,… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19- Continued Progress with VK0214 for X-ALD; Expect to Commence Phase 1 Clinical Study in … […]

No Picture
News

Evofem Biosciences to Report Second Quarter 2019 Results and Provide Corporate Update on August 6, 2019

— Conference Call Scheduled for 11:00 a.m. EDT —

SAN DIEGO, July 30, 2019 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the second quarter ended June 30… […]